Bergen - Reference is made to the stock exchange announcement by BerGenBio ASA (the 'Company') on 30 November 2023 regarding the final results of the first exercise period for the warrants ('Warrants') issued in connection with the rights issue, which resulted in an allocation of 68,156,682 new shares in the Company ('New Shares') to investors holding Warrants.
The share capital increase pertaining to the New Shares is now registered with the Norwegian Register of Business Enterprises. After this, the Company's new registered share capital is NOK 268,868,921.40 divided into 2,688,689,214 shares, each with a nominal value of NOK 0.10.
Contact:
Martin Olin
Email: ir@bergenbio.com
Rune Skeie
Email: rune.skeie@bergenbio.com
About BerGenBio ASA
BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including cancer and severe respiratory infections. The Company is focused on its proprietary lead candidate, bemcentinib, a potentially first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC and severe respiratory infections. BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The company is listed on the Oslo Stock Exchange (ticker: BGBIO).
(C) 2023 Electronic News Publishing, source ENP Newswire
BERGENBIO ASA 
